StocksMarket.in

Cipla — While COVID scope continues, watch out for FY23

May 17
11:24 2021

Just when it seemed that Covid tailwinds are waning for Cipla, the drug maker has repositioned itself for the opportunities emerging from the second wave of the pandemic

Anubhav Sahu

Archives